Foresight Diagnostics’ ctDNA Liquid Biopsy Platform Streamlines Treatment of B-Cell Lymphoma
Detection of ctDNA levels with the assay was correlated with detected changes in tumor burden in B-cell lymphoma patients treated with acalabrutinib.
Detection of ctDNA levels with the assay was correlated with detected changes in tumor burden in B-cell lymphoma patients treated with acalabrutinib.
The automated PS-10 sample preparation system streamlines workflows and standardizes clinical flow cytometry testing.
The new technology has proved to be up to 90% accurate in tests involving 200 human cancer samples and normal DNA.
A new study shows the MultiOmyx profile could improve disease assessment for both diseases using multiplex proteins.
Read MoreUltra-sensitive detection of minimal residual disease now available to more people with blood cancers.
Read MoreAssay can aid physicians in better risk stratification and treatment of patients with diffuse large B-cell lymphoma.
Read MoreThe test has been shown to offer sensitivity for the detection of residual cancer cells in marrow or blood.
Read MoreWith so many types of lymphoma, there’s a wide range of corresponding lab tests to detect their presence in patients. Here, CLP takes a look at testing for the most common type of lymphoma (diffuse large B-cell
Read More